Exhibit 99.1
Joint Filing Agreement
The undersigned hereby agree that the foregoing Statement on Schedule 13G with respect to the shares of Common Stock of CTI BioPharma Corp., and any further amendments thereto executed by each and any of the undersigned, shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.
Dated: January 29, 2016
| NB PUBLIC EQUITY K/S | |||
| By: | NB PUBLIC EQUITY KOMPLEMENTAR ApS, | ||
| its general partner | |||
| By:/s/ Cora Madsen* | |||
| Name: Cora Madsen | |||
| Title: Director | |||
| NB PUBLIC EQUITY KOMPLEMENTAR ApS | |||
| By: | /s/ Cora Madsen* | ||
| Name: Cora Madsen | |||
| Title: Director | |||
| /s/ Cora Madsen * | |||
| Cora Madsen | |||
| /s/ Florian Schönharting* | |||
| Florian Schönharting | |||
| *By: | /s/ James E. Dawson | ||
| James E. Dawson, as attorney-in-fact | |||
